3D Movie Viewing vs Occlusion for Treating Amblyopia in Children (VISTA3D)
Efficacy of 3D Movie Viewing Versus Occlusion on Stereopsis and Visual Function in Children With Amblyopia: A Randomized Controlled Trial
Amblyopia is a common childhood visual disorder that affects vision in one eye and can also impair depth perception (stereopsis). Standard treatment typically involves occlusion therapy (patching the stronger eye), which improves visual acuity but often does not fully restore binocular vision.
This study aims to evaluate whether watching 3D movies, combined with occlusion therapy, improves visual outcomes more than occlusion therapy alone in children with amblyopia. The immersive nature of 3D content may stimulate binocular vision and enhance treatment effectiveness.
In this randomized controlled trial, children aged 4 to 14 years with amblyopia will be assigned to one of two groups: one group will receive standard occlusion therapy, while the other will receive occlusion combined with weekly 3D movie sessions. After an initial phase, all participants will have access to 3D viewing sessions.
The study will assess improvements in depth perception, visual acuity, and eye alignment over time. The goal is to determine whether this combined approach provides additional benefits and could be used as a complementary therapy for amblyopia.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Amblyopia is the leading cause of monocular visual impairment in children, with a prevalence of approximately 2-3%. It is commonly associated with strabismus and/or anisometropia and is characterized by reduced visual acuity and deficits in binocular vision, particularly stereopsis. While conventional treatments such as refractive correction and occlusion therapy are effective in improving visual acuity, many patients retain residual deficits in stereopsis and binocular function.
Recent advances in amblyopia treatment have focused on binocular approaches, including perceptual learning, dichoptic training, and virtual reality-based interventions. These methods aim to stimulate binocular interaction and reduce suppression of the amblyopic eye. Among these approaches, 3D movie viewing represents a naturalistic and engaging stimulus that introduces large binocular disparities and may promote binocular integration in a child-friendly environment.
Preliminary evidence from a pilot study conducted by our group demonstrated that a single 3D movie session can produce significant and sustained improvements in stereopsis and visual acuity in children with a history of amblyopia. However, this study lacked a control group and involved only a single exposure session.
The present study is a prospective, randomized, controlled, single-center clinical trial designed to evaluate the efficacy of repeated 3D movie viewing sessions combined with occlusion therapy compared to occlusion therapy alone. Participants will be randomly assigned to either an experimental group (3D viewing plus occlusion) or a control group (occlusion alone). The intervention will consist of 3 to 6 weekly sessions of 3D movie viewing, each lasting approximately 90-120 minutes.
The study includes two phases: an initial comparative phase in which outcomes between groups are assessed after three sessions, and a second phase in which all participants are exposed to additional 3D sessions to evaluate cumulative effects. Assessments will be conducted at baseline (T0), after the first phase (T1), and after completion of all sessions (T2).
Primary outcome measures include stereopsis (measured in log arcseconds), visual acuity (logMAR), and ocular deviation (prism diopters). Secondary outcomes include sensory and motor characteristics (fusion, suppression, retinal correspondence), treatment adherence, and patient-reported satisfaction and quality of life.
Outcome assessors will be masked to group allocation to reduce bias. The study also aims to explore factors influencing treatment response, including age and type of amblyopia.
This trial seeks to determine whether 3D movie viewing can serve as an effective, engaging, and non-invasive adjunct to conventional amblyopia treatment, with potential implications for improving both visual function and patient adherence.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Laura Asensio Jurado, PhD
- Numero di telefono: 0034636760450
- Email: asensiojlaura@upc.edu
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Descrizione
Inclusion Criteria:
Children aged 4 to 14 years Diagnosis of unilateral amblyopia (anisometropic, strabismic, or mixed) Interocular visual acuity difference ≥ 0.2 logMAR (equivalent to ≥ 2 Snellen lines) Ability to understand and follow age-appropriate instructions Written informed consent from parents or legal guardians Child assent obtained when applicable
Exclusion Criteria:
Previous treatment for amblyopia Ocular surgery within the last 6 months Strabismus with deviation greater than 10 prism diopters Presence of other ocular pathologies affecting vision (e.g., cataract, nystagmus, ptosis, corneal opacity, retinal disease, optic neuropathy) Neurological or cognitive impairment preventing compliance with study procedures Prior intensive exposure to 3D movies or virtual reality/3D video games that could act as a confounding factor Refusal of the child or family to participate
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: 3D Movie Viewing + Occlusion
Participants will receive standard occlusion therapy combined with 3D movie viewing sessions.
The intervention consists of 3 weekly sessions (Phase 1), followed by 3 additional sessions (Phase 2), each lasting 90-120 minutes, in a controlled environment.
|
Participants will watch 3D movies using active shutter glasses in a controlled environment.
Sessions will be conducted once weekly, each lasting approximately 90-120 minutes, over a total of 3 to 6 sessions.
This intervention aims to stimulate binocular vision through exposure to large binocular disparities in an immersive and engaging setting.
Standard occlusion therapy of the non-amblyopic eye prescribed according to clinical guidelines and amblyopia severity.
Treatment is performed at home for a specified number of hours per day, depending on clinical indication, with the goal of improving visual acuity in the amblyopic eye.
|
|
Comparatore attivo: Occlusion Therapy
Participants will receive standard occlusion therapy according to clinical guidelines based on amblyopia severity during Phase 1.
In Phase 2, participants will also undergo 3D movie viewing sessions.
|
Standard occlusion therapy of the non-amblyopic eye prescribed according to clinical guidelines and amblyopia severity.
Treatment is performed at home for a specified number of hours per day, depending on clinical indication, with the goal of improving visual acuity in the amblyopic eye.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Stereopsis (RANDOT)
Lasso di tempo: Baseline (T0) to 3 weeks (T1)
|
Stereopsis will be assessed using a validated stereopsis test (Random Dot 2 Test).
Results will be expressed in log arcseconds.
|
Baseline (T0) to 3 weeks (T1)
|
|
Change in Visual Acuity
Lasso di tempo: Baseline (T0) to 3 weeks (T1)
|
Visual acuity will be measured using standardized ETDRS charts and expressed in logMAR.
|
Baseline (T0) to 3 weeks (T1)
|
|
Change in Ocular Deviation
Lasso di tempo: Baseline (T0) to 3 weeks (T1)
|
Ocular deviation will be assessed using cover test and prism bars at distance (6 m) and near (40 cm), expressed in prism diopters (PD), distinguishing esotropia and exotropia.
|
Baseline (T0) to 3 weeks (T1)
|
|
Change in Stereopsis ( StereoTAB)
Lasso di tempo: Baseline (T0) to 3 weeks (T1)
|
Stereopsis will be assessed using a validated stereopsis test (StereoTAB Test).
Results will be expressed in log arcseconds.
|
Baseline (T0) to 3 weeks (T1)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Binocular Function (Fusion and Suppression)
Lasso di tempo: Baseline (T0) to 3 weeks (T1)
|
Binocular sensory status will be evaluated using the Worth 4 Dot test to assess fusion and suppression.
|
Baseline (T0) to 3 weeks (T1)
|
|
Retinal Correspondence
Lasso di tempo: Baseline (T0) to 3 weeks (T1)
|
Retinal correspondence will be assessed using the Bagolini striated lenses test.
|
Baseline (T0) to 3 weeks (T1)
|
|
Treatment Adherence
Lasso di tempo: Up to 6 weeks
|
Adherence will be measured as the number of completed sessions and reported hours of occlusion therapy.
|
Up to 6 weeks
|
|
Adverse Events and Visual Symptoms
Lasso di tempo: Up to 6 weeks
|
Occurrence of symptoms such as headache, visual fatigue, or blurred vision will be recorded using a structured questionnaire.
|
Up to 6 weeks
|
Collaboratori e investigatori
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Bridgeman B. Restoring adult stereopsis: a vision researcher's personal experience. Optom Vis Sci. Jun 2014;91(6):e135-9. doi:https://doi.org/10.1097/opx.0000000000000272
- Asensio-Jurado L, Argilés M, Quevedo-Junyent L, Mestre C, Levi DM. Can viewing a 3D movie improve visual function in children with a history of amblyopia and neurotypical children?: A pilot study. PLoS One. 2024;19(6):e0305401. doi:https://doi.org/10.1371/journal.pone.0305401
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie degli occhi
- Errori di rifrazione
- Disturbi della vista
- Disturbi della sensibilità
- Malattie dei nervi cranici
- Disturbi della motilità oculare
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Ambliopia
- Strabismo
- Anisometropia
Altri numeri di identificazione dello studio
- PDE2LAJ.VISTA3D
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .